Elite Pharmaceuticals, Inc., a health care company based in Northvale, United States, has been actively engaged in the research, development, licensing, and manufacturing of both new and generic oral controlled-release pharmaceutical products. The company’s focus spans across various therapeutic areas, including cardiovascular, antidiabetic, anti-infective agents, as well as cough and cold preparations. Currently, Elite Pharmaceuticals is conducting clinical trials for its pain management products, underscoring its commitment to expanding its portfolio in critical therapeutic areas.
As of November 10, 2025, the company’s stock is traded on the OTC Bulletin Board, with a close price of $0.65. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $0.82 on June 17, 2025, and a 52-week low of $0.27 on April 6, 2025. This fluctuation reflects the dynamic nature of the pharmaceutical industry and the challenges faced by companies in this sector.
Elite Pharmaceuticals Inc. has a market capitalization of approximately $679.77 million, indicating its substantial presence in the pharmaceutical industry. However, the company’s financial metrics reveal some challenges, with a price-to-earnings ratio of -43.32. This negative ratio suggests that the company is currently not generating profits, which is not uncommon for companies heavily invested in research and development.
Founded on July 23, 1998, Elite Pharmaceuticals has been publicly traded since its inception, providing investors with opportunities to participate in its growth and development. The company’s strategic focus on controlled-release formulations aims to enhance patient compliance and therapeutic outcomes, positioning it as a key player in the pharmaceutical landscape.
For more detailed information about Elite Pharmaceuticals’ activities, offerings, and strategic initiatives, stakeholders are encouraged to visit their official website at www.elitepharma.com . The company continues to prioritize innovation and patient care, striving to deliver effective and accessible pharmaceutical solutions.
